Skip to main content
SpringerLink
Log in

Toxicological Profile of Piroxicam-β-Cyclodextrin

  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

Acute toxicity studies of piroxicam-β-cyclodextrin have shown gastrointestinal side effects that are attributable to the active constituent of the complex and are characteristic of nonsteroidal anti-inflammatory drugs. The oligosaccharide vehicle, β-cyclodextrin, has a negligible oral absorption and is reported to be nontoxic. Studies of repeated administration of piroxicam-β-cyclodextrin for periods of up to 26 weeks have shown that the compound is well tolerated. There is no evidence that piroxicam-β-cyclodextrin causes any mutagenic or clastogenic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Gergely V, Sebestyen S, Virag S. Toxicity study of β-cyclodextrin. In Szejtli J (Ed.) Proceedings of the 1st International Symposium on Cyclodextrins, pp. 109–113, Reidel Publishing Co., Dordrecht, 1982

    Google Scholar 

  • Gerloczy A, Fonagy A, Keresztes P, Perlaky L, Szejtli J. Absorption, distribution, excretion and metabolism of orally administered 14C-β-cyclodextrin in rat. Arzneimittel-Forschung 35: 1042–1047, 1985

    PubMed  CAS  Google Scholar 

  • Makita T, Ojima N, Hashimoto Y, Ide H, Tsuji M, Fujisaki T. Chronic oral toxicity study of β-cyclodextrin in rats. Oyo Yakuri 10: 449–458, 1975

    CAS  Google Scholar 

  • Matsuda K, Merea Y, Segawa Y, Uchida I, Yokomine A, Takagi K. Acute toxicity study of β-cyclodextrin (β-CD) in mice and rats. Oyo Yakuri 26: 287–291, 1983

    CAS  Google Scholar 

  • Nambu N, Kikuchi K, Kikuchi T, Takahashi Y, Ueda H, et al. Influence of inclusion of nonsteroidal antiinflammatory drugs with β-cyclodextrin on the irritation to stomach of rats upon oral administration. Chemical and Pharmaceutical Bulletin 26: 3609–3612, 1978

    Article  CAS  Google Scholar 

  • Szejtli J, Sebestyen G. Resorption, metabolism and toxicity studies on the peroral application of β-cyclodextrin. Starch Stark 31: 385–389, 1979

    Article  CAS  Google Scholar 

  • Wiseman EH. Pharmacological studies with a new class of nonsteroidal anti-inflammatory agents — the oxicams — with special reference to piroxicam (Feldene®). American Journal of Medicine 72(2A): 2–8, 1982

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacological and Toxicological Research Laboratories, Chiesi Farmaceutici SpA, via Palermo 26/A, 43100, Parma, Italy

    S. Cadel &  S. Bongrani

Authors
  1. S. Cadel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Bongrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cadel, S., Bongrani, S. Toxicological Profile of Piroxicam-β-Cyclodextrin. Drug Invest 2 (Suppl 4), 37–41 (1990). https://doi.org/10.1007/BF03258225

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258225

Keywords

Search

Navigation